May 18, 2026 Biotheryx’s Phase 1 Study Shows Promising Results for BTX-9341, a Novel CDK4/6 Degrader in HR+/HER2- Breast Cancer
April 22, 2026 Return only the content requested, in English without any additional comments or text. Michael and Susan Dell Donate $750 Million to University of Texas at Austin to Transform Patient Care
